Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: ORGANOPLATINUM COMPOUNDS - ADVERSE EFFECTS , . Treffer: 4
2017
Eisterer, W; Piringer, G; DE Vries, A; Öfner, D; Greil, R; Tschmelitsch, J; Samonigg, H; Sölkner, L; Gnant, M; Thaler, J; Austrian Breast and Colorectal Cancer Study Group
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Anticancer Res. 2017; 37(5):2683-2691
Doi: 10.21873/anticanres.11617
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2011
Mikalauskas, S; Mikalauskiene, L; Bruns, H; Nickkholgh, A; Hoffmann, K; Longerich, T; Strupas, K; Büchler, MW; Schemmer, P
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Amino Acids. 2011; 40(4):1139-1150
Doi: 10.1007/s00726-010-0737-6
Web of Science
PubMed
FullText
FullText_MUG
2002
Gamelin, E; Gamelin, L; Bossi, L; Quasthoff, S
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
SEMIN ONCOL 2002 29: 21-33.
Doi: 10.1053/sonc.2002.35525
Web of Science
PubMed
FullText
FullText_MUG
Lersch, C; Schmelz, R; Eckel, F; Erdmann, J; Mayr, M; Schulte-Frohlinde, E; Quasthoff, S; Grosskreutz, J; Adelsberger, H
Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Clin Colorectal Cancer. 2002; 2(1): 54-58.
Doi: 10.3816/CCC.2002.n.011
PubMed
FullText
FullText_MUG